On its way to reaching the market
TARGET CHANGE
CHANGE IN EPS2018 : € -0.94 vs -0.36 ns
2019 : € -0.79 vs -0.06 ns
We have fine-tuned our numbers in the back of the group’s latest comments as well as integrating the new NTE to be developed (Terbutaline) instead of Apomorphine which is now on stand-by. This said, short-term numbers have little meaning (other than the group’s cash-burn) since first sales should be booked in FY20.
CHANGE IN NAV€ 19.0 vs 18.2 +4.78%
We have adjusted our ....
05 Sep 2018
On its way to reaching the market (Crossject)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
On its way to reaching the market (Crossject)
Crossject SA (ALCJ:PAR) | 0 0 (-3.4%) | Mkt Cap: 38.7m
- Published:
05 Sep 2018 -
Author:
Fabrice Farigoule -
Pages:
2
On its way to reaching the market
TARGET CHANGE
CHANGE IN EPS2018 : € -0.94 vs -0.36 ns
2019 : € -0.79 vs -0.06 ns
We have fine-tuned our numbers in the back of the group’s latest comments as well as integrating the new NTE to be developed (Terbutaline) instead of Apomorphine which is now on stand-by. This said, short-term numbers have little meaning (other than the group’s cash-burn) since first sales should be booked in FY20.
CHANGE IN NAV€ 19.0 vs 18.2 +4.78%
We have adjusted our ....